Bumper Hemp Crops Promise Profit for Farmers and Cannabis Companies
New York NY – November 1, 2018 – This year will see the largest U.S. hemp crop since changes to federal law created an avenue for production to start again, turning over decades of fallowed industry. Thousands of acres of hemp will be harvested across 19 states. Kentucky is seeing particularly good crops, due […]
Sugarmade Executes on $40 Million Definitive Agreement to Acquire Sky Unlimited, LLC Creating Hydroponic Supply Powerhouse
MONROVIA, California, November 1, 2018 – Sugarmade, Inc. (OTCQB:SGMD) today announces the signing of a binding Definitive Agreement to acquire Sky Unlimited, LLC, which through its AthenaUnited.com operations and website offers multiple popular hydroponic brands to several growing agricultural cultivation sectors. As a result of this acquisition, Sugarmade is raising its revenue guidance for calendar […]
Hydroponic Cultivation Supply Business Dramatically Increasing as Global Cannabis Industry Explodes
Palm Beach, FL – (November 1, 2018) – Now that the legal marijuana and global cannabis markets have exploded, a spotlight is shining bright on the cultivation and growing services segment of the industry, that includes Hydroponic systems and accessories. Hydroponically grown plants grow up to 50% faster and produce higher yields of better quality […]
Moleculin Announces Significant Milestone Achieved in Glioblastoma Trial
WP1066 demonstrating drug bioavailability in on-going Phase 1 clinical trial HOUSTON – November 1, 2018 – Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf […]
Positive Developments for Treating Patients With Recurrent Malignant Tumors Significant for Novel Therapeutic Strategies
Palm Beach, FL – (November 1, 2018) – Multiple myeloma (MM) known as a plasma cell malignancy that affects 14,000 patients per year are fueling the development and clinical activities for new therapies to treat these malignancies. Recent clinical trial results are suggesting that Stat3 Inhibitor – WP1066 may reduce Stat activation through a unique […]
